

AMENDMENT

Please amend the application without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

In the Claims

1. (Currently amended) A conjugate comprising a first sequence and a second sequence, wherein:

the first sequence comprises an antibody or antibody fragment comprising a variable region and which binds to an antigen presenting cell (APC) surface molecule, wherein the APC surface molecule is selected from the group consisting of an MHC class II molecule, CD205 (DEC205), CD204, CD14, CD206, TLRs, Langerin (CD207), DC-SIGN (CD209), CD68, CD83, CD33, CD54 and BDCA-2,3,4; and

wherein the second sequence comprises a Notch ligand or a fragment thereof, wherein the second sequence comprises a Notch ligand DSL domain and at least one EGF-like repeat, wherein the Notch ligand is selected from the group consisting of human Delta 1 comprising the amino acid sequence of SEQ ID NO: 40, human Delta 3 comprising the amino acid sequence of SEQ ID NO: 41, human Delta 4 comprising the amino acid sequence of SEQ ID NO: 42, human Jagged 1 comprising the amino acid sequence of SEQ ID NO: 43, and Jagged 2 comprising the amino acid sequence of SEQ ID NO: 44, and wherein the second sequence retains Notch signalling signaling activity.

2. (Original) The conjugate according to claim 1, wherein the conjugate is a fusion protein.

3-17. (Cancelled)

18. (Previously presented) The conjugate according to claim 1, wherein the first sequence is an antibody or antibody fragment which binds to an MHC class II molecule.

19-28. (Cancelled)

29. (Previously presented) A conjugate prepared by

(a) transforming a host cell with an expression vector comprising a polynucleotide sequence encoding the conjugate of claim 1; and

(b) culturing the host cell under conditions which provide for expression of the conjugate.

30. (Withdrawn) A method of targeting a protein for Notch signalling modulation, or a polynucleotide coding therefor, to an APC comprising exposing the APC to the conjugate according to claim 1.

31. (Original) A composition comprising the conjugate of claim 1 and a pharmaceutically acceptable excipient, diluent or carrier.

32. (Withdrawn) A method of preventing or treating a disease or infection a subject in need thereof, comprising administering the conjugate according to claim 1 to the subject.

33. (Withdrawn) The method according to claim 32, wherein the disease is a T-cell mediated disease.

34-36. (Cancelled)